SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.
- With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
- NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
- NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
- "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.